logo-loader
viewProactive Group

Dermira stock rises after positive trial for its lebrikizumab dermatitis treatment

A Phase 2b trial of lebrikizumab met its primary endpoint of demonstrating greater improvements in the Eczema Area and Severity Index score

1552937193_shutterstock_386047579.jpg
The California-based biotech develops therapies to treat dermatologic diseases

Dermira Inc (NASDAQ:DERM) extended its gain Tuesday a day after the biotech reported encouraging results in a mid-stage trial of lebrikizumab, its treatment for moderate to severe atopic dermatitis, a condition that makes a person’s skin red and itchy.

A Phase 2b trial of lebrikizumab met its primary endpoint of demonstrating greater improvements in the Eczema Area and Severity Index (EASI) score. Dermira said all three doses evaluated in the dose-ranging study — 125 milligrams every four weeks, 250mg every four weeks and 250mg every two weeks — met the primary endpoint of showing greater improvement in the EASI index at week 16 compared with a placebo.

Investors sent shares in the Menlo Park, California-based company up 1.8% to $12.84 in Tuesday's premarket trading after soaring almost 85% Monday.

READ: PhaseBio Pharmaceuticals jumps on rosy Phase 1 trial for ticagrelor reversal agent

The safety profile was consistent with prior studies.

"I have many patients for whom current therapies do not adequately address their needs," Dr. Emma Guttman-Yassky, a leading study investigator, said in a statement. "These data show that lebrikizumab may offer a targeted, effective and well-tolerated therapeutic approach." 

Lebrikizumab is a potent inhibitor of interleukin-13, or IL-13, a substance secreted by certain cells that causes type 2 inflammation, leading to itching, skin thickening and infection.

In September 2017, Dermira acquired the exclusive, worldwide rights to develop and commercialize lebrikizumab for atopic dermatitis and other potential indications pursuant to a licensing agreement with Roche.

–This story has been updated to give the latest stock price–

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Instem bolsters its platform with Leadscope acquisition

Instem PLC (LON:INS) CEO Phil Reason tells Proactive the UK-based software solutions and services provider has bolstered its platform by acquiring Ohio-based Leadscope Inc.  Reason says Leadscope specialises in computer modelling, and will easily integrate into its current software...

21 minutes ago

2 min read